Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.
FC
Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.
Second-line treatment in patients with CLL
|
fludarabine
(Round to nearest 2.5 mg) | 25 mg /m² | IV | Days 1-3 * |
|
cyclophosphamide
(Round to nearest 10 mg) | 250 mg /m² | IV | Days 1-3 * |
REPEAT EVERY 28 DAYS
For 6 cycles in the absence of disease progression or unacceptable toxicity
Moderate
Other Supportive Care:
Also refer to CCO Antiemetic Summary
- Consider prophylactic growth factor support, antiviral and PCP prophylaxis (according to local practice).
- If high volume disease (e.g. WBC > 25 x 109/L), consider prophylaxis for tumour lysis
Doses should be modified according to the protocol by which the patient is being treated
Dosage with toxicity
Suggested dose levels for fludarabine are 25 mg/m2 , 20 mg/m2 and 15 mg/m2 .
Suggested dose levels for cyclophosphamide are 250 mg/m2 , 200 mg/m2 and 150 mg/m2 .
|
Toxicity
|
Fludarabine
(% previous dose)
|
Cyclophosphamide
(% previous dose)
|
|
Febrile Neutropenia;
Grade 4 myelosuppression ≥ 7 days; Thrombocytopenic bleeding;
1-2 week delay prior cycle
|
↓ 1 dose level or G-CSF (for isolated neutropenia) 1
|
↓ 1 dose level or G-CSF (for isolated neutropenia) 1
|
|
Grade 3 non-hematologic / organ
|
↓ 1 dose level 1
|
↓ 1 dose level 1
|
|
Grade 4 non-hematologic / organ
|
Discontinue
|
Discontinue
|
|
Any grade autoimmune, neurotoxicity, pneumonitis, or
> 2 week delay prior cycle
|
Discontinue
|
Discontinue
|
|
1. Do not retreat until non-hematologic / organ toxicity recovered to ≤ grade 2, ANC to ≥ 1 x 109/L and platelets ≥ 80 x 109/L (or to baseline levels).
|
||
Hepatic Impairment
|
Bilirubin
|
|
AST / ALT
|
Fludarabine
(% usual dose)
|
Cyclophosphamide
(% usual dose)
|
|
1-2 x ULN
|
|
|
No data available; use with caution
|
No change
|
|
>2-4 X ULN
|
And/or
|
>2-4 X ULN
|
Caution
|
|
|
> 4 x ULN
|
And/or
|
> 4 x ULN
|
Caution
|
Renal Impairment
|
Creatinine Clearance (mL/min)
|
Fludarabine
(% usual dose)
|
Cyclophosphamide
(% usual dose)
|
|
>50 - 70
|
50%
|
100%
|
| 30 - 50 | 50% | 75% |
|
10 - <30
|
Discontinue
|
75%
|
|
<10
|
Use with extreme caution or Discontinue
|
Refer to fludarabine, cyclophosphamide drug monograph(s) for additional details of adverse effects.
|
Most Common Side Effects |
Less Common Side Effects, but may be Severe or Life-Threatening |
|
|
Refer to fludarabine, cyclophosphamide drug monograph(s) for additional details.
Recommended Clinical Monitoring
- CBC; baseline and before each cycle. Interim counts should be done in first cycle and repeated if dose modification necessary.
- Baseline and regular liver and renal function tests.
- Clinical toxicity assessment (including gastrointestinal, infection, autoimmune, dehydration, cystitis, pulmonary, skin, CNS effects); at each visit
-
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
back to top
Fludarabine and cyclophosphamide drug monographs, Cancer Care Ontario.
Hallek M, Fingerle-Rowson G, Fink A, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 325.
Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-65.
October 2017 Replaced regimen category with evidence-informed
Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.